Souhaitez-vous accéder aux communiqués récents ?

Oncolytics announced more than 20 patients pre-identified for REO 033 colorectal cancer trial and scheduled Type D meeting with the FDA.

FDA grants De Novo classification to Claria Medical for device designed to improve the safety and efficiency of hysterectomy procedures

FORT LEE, N.J., July 10, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...

First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development Novel 13-point edited...

Initiation of the TRICURE US IDE pivotal study represents the first of next-generation TTVR devices to enroll patients in the US  Minneapolis, MN, USA and Paris, France and Munich, Germany, 9 July...

60 Degrees Pharma (Nasdaq: SXTP) secures exclusive option to develop castanospermine for tick-borne diseases, expanding its infectious disease pipeline.

FDA alignment on a single-dose Phase 3 study design and potential single-trial registration pathway further strengthens the Company's clinical development program for urcosimodCompany unveils NEPTUNE...

– Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol — – FDA agreed that a single pivotal Phase 3...

Agios announces that the FDA has accepted its sNDA for mitapivat in sickle cell disease with a Priority Review

Silver Spring, MD, July 01, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today approved Tregzi, the first regulatory T (Treg) cell-based immunotherapy for improving chronic...